Heart and Estrogen/progestin

As of 1995, almost 38% of all women 50 to 75 years of age were using HRT.1 It was in 1996 that the United States Preventive Services Task Force (USPSTF) first published its recommendations that not all postmenopausal women should be prescribed HRT, but rather, therapy should be individualized based on risk factors. This recommendation was further supported with publication of the Heart and Estrogen/Progestin Replacement Study (HERS) in 1998, which demonstrated that women who had established CHD were at an increased risk of experiencing a myocardial infarction within the first year of HRT use compared with a similar group of women without CHD risk factors. As a result, the authors concluded that HRT is not recommended for the secondary prevention of CHD.2 Then, in 2002, the Women s Health Initiative (WHI) report was published. This trial demonstrated that HRT was not protective against CHD but... 

HERS Heart and Estrogen/Progestin Replacement Study... 

Grady D, Brown JS, Vittinghoff E, Applegate W, Varner E, Snyder T (2001) Postmenopausal hormones and incontinence the heart and estrogen/progestin replacement study. Obstet Gynecol 97 116-120... 

Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA. 1998 280 605-613. 

The Heart and Estrogen/Progestin Replacement Study (HERS) was undertaken to determine whether estrogen plus progestin therapy alters the risk for CHD events in postmenopausal women with established CAD. A total of 2763 women (mean age 66.7 years)... 

WHI, Women s Health Initiative HERS, Heart and Estrogen/Progestin Replacement Study ERA, Estrogen Replacement in Atherosclerosis WEST, Women s Estrogen for Stroke Trial ESPRIT, Estrogen in the Prevention of Reinfarction. 

Kanaya AM, Herrington D, Vittinghoff E, et al. Glycemic effects of postmenopausal hormone therapy The Heart and Estrogen/Progestin Replacement Study. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2003 138 1-9. 

Hlatky MA, Boothroyd D, Vittnghoff E, et al. for the HERS research group. Quality of life and depressive symptoms in postmenopausal women after receiving hormone therapy Results from the Heart and Estrogen/Progestin Replacement Study (HERS) Trial. JAMA 2002 287 591-597. 

---